Restricted accessResearch articleFirst published online 2023-10
Return of Vocal Fold Motion and Surgical Preservation of Invaded Recurrent Laryngeal Nerves After the Use of Neoadjuvant Therapy in Patients Presenting with Advanced Thyroid Cancer and Vocal Fold Paralysis: The Lazarus Effect
BrooksJA, Abdelhamid AhmedAH, Al-QurayshiZ, et al.Recurrent laryngeal nerve invasion by thyroid cancer: Laryngeal function and survival outcomes. Laryngoscope, 2022; 132(11):2285–2292; doi: 10.1002/lary.30115.
2.
SchneiderR, RandolphGW, DionigiG, et al.International neural monitoring study group guideline 2018 part I: Staging bilateral thyroid surgery with monitoring loss of signal. Laryngoscope, 2018; 128(Suppl. 3):S1–S17; doi: 10.1002/lary.27359.
3.
NaunheimMR, von SneidernM, HustonMN, et al.Patient experiences with thyroid nodules: A qualitative interview survey. OTO Open, 2023; 7(1):e39.
4.
SpectorBC, NettervilleJL, BillanteC, et al.Quality-of-life assessment in patients with unilateral vocal cord paralysis. Otolaryngol Neck Surg, 2001; 125(3):176–182; doi: 10.1067/mhn.2001.117714.
5.
FrancisDO, ShermanAE, HovisKL, et al.Life experience of patients with unilateral vocal fold paralysis. JAMA Otolaryngol Head Neck Surg, 2018; 144(5):433–439; doi: 10.1001/jamaoto.2018.0067.
6.
KamaniD, DarrEA, RandolphGW. Electrophysiologic monitoring characteristics of the recurrent laryngeal nerve preoperatively paralyzed or invaded with malignancy. Otolaryngol-Head Neck Surg, 2013; 149(5):682–688; doi: 10.1177/0194599813504735.
7.
ShindoML, CaruanaSM, KandilE, et al.Management of invasive well-differentiated thyroid cancer: An American Head and Neck Society consensus statement. AHNS consensus statement. Head Neck, 2014; 36(10):1379–1390; doi: 10.1002/hed.23619.
8.
NishidaT, NakaoK, HamajiM, et al.Preservation of recurrent laryngeal nerve invaded by differentiated thyroid cancer. Ann Surg, 1997; 226(1):85–91; doi: 10.1097/00000658-199707000-00012.
9.
ShonkaDC, HoA, ChintakuntlawarAV, et al.American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. Head Neck, 2022; 44(6):1277–1300; doi: 10.1002/hed.27025.
10.
Abdelhamid AhmedAH, RussellMD, KyriazidisN, et al.A phase 2 study of neoadjuvant lenvatinib in locally advanced invasive thyroid cancer. J Clin Oncol, 2023; 41(16 Suppl.):TPS6105; doi: 10.1200/JCO.2023.41.16_suppl.TPS6105.
